| Nov 18 |
Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024
|
| Oct 30 |
Larimar Therapeutics GAAP EPS of -$0.24 beats by $0.14
|
| Oct 30 |
Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results
|
| Oct 16 |
Larimar initiated with bullish view at Oppenheimer on lead drug
|
| Oct 7 |
Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential
|
| Oct 3 |
Larimar started at outperform by Wedbush on FA drug candidate
|
| Sep 19 |
Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research
|
| Sep 12 |
Jones Research starts Larimar at Buy, cites lead asset nomlabofusp
|
| Aug 27 |
Larimar Therapeutics to Participate in Upcoming Investor Conferences
|
| Aug 7 |
Larimar Therapeutics GAAP EPS of -$0.34
|
